Several Phase III studies are currently ongoing assessing the combination of PD-(L)1 antibodies and VEGFR TKIs, including pembrolizumab combined with lenvatinib, atezolizumab plus cabozantinib, and camrelizumab (SHR-1210) with apatinib in advanced HCC, the results of which will clarify the utility of antiangiogenic TKIs as immunomodulators in conjunction with CPIs (Table 3) (190). The gene discussed is CD274; the disease is hepatocellular carcinoma.